<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204673">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000299</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-09260-2</org_study_id>
    <secondary_id>P50DA009260</secondary_id>
    <secondary_id>P50-09260-2</secondary_id>
    <nct_id>NCT00000299</nct_id>
  </id_info>
  <brief_title>Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2</brief_title>
  <official_title>Rapid Opiate Detoxification &amp; Naltrexone Induction Using Bup.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop a clinical protocol to detoxify patients from
      opiates to naltrexone using buprenorphine and to develop pilot data for a grant application
      for a controlled study of the efficacy of the new clinical protocol for outpatients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Opiate craving</measure>
    <time_frame>10 test days</time_frame>
    <safety_issue>No</safety_issue>
    <description>opiate craving is measured on each test day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opiate withdrawal symptoms</measure>
    <time_frame>10 test days</time_frame>
    <safety_issue>No</safety_issue>
    <description>opiate withdrawal symptoms are documented for each test day</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <arm_group>
    <arm_group_label>buprenorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>depot buprenorphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>buprenorphine and ultra-low dose naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>depot buprenorphine and naloxone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <arm_group_label>buprenorphine</arm_group_label>
    <arm_group_label>buprenorphine and ultra-low dose naloxone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Males/Females, ages 21-50. Opiate dependence according to DSM-IV criteria. Self-reported
        use within the last 30 days. Agreeable to conditions of study and signed informed consent.

        Exclusion Criteria:

        psychiatric disorder that requires medication therapy. History of seizures. Pregnant
        and/or nursing women. Dependent on etoh or benzodiazepines or other sedative-hypnotics.
        Acute hepatitis. Other medical conditions that deem participation to be unsafe.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Ling, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friends Research Institute, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friends Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 17, 2013</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Walter Ling</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
